Title: 2016 ACVIM Forum Research Abstract Program Document date: 2016_5_31
ID: 2y1y8jpx_554
Snippet: These findings suggest that FGF-23 concentrations rise in canine CKD before other traditional markers of RHPT do. Consequently, FGF-23 concentrations should be considered as an early indicator of disease progression, RHPT, and potential target for therapeutic intervention. Erythropoiesis-stimulating agents are currently recommended for veterinary patients with anemia secondary to chronic kidney disease (CKD). Darbepoetin alfa (darbepoetin) has re.....
Document: These findings suggest that FGF-23 concentrations rise in canine CKD before other traditional markers of RHPT do. Consequently, FGF-23 concentrations should be considered as an early indicator of disease progression, RHPT, and potential target for therapeutic intervention. Erythropoiesis-stimulating agents are currently recommended for veterinary patients with anemia secondary to chronic kidney disease (CKD). Darbepoetin alfa (darbepoetin) has replaced epoetin due to a three-fold longer half-life allowing for less frequent dosing. Also, darbepoetin is perceived to be less likely to elicit formation of anti-erythropoietin antibodies resulting in pure red cell aplasia (PRCA). A previous study examined the efficacy of darbepoetin in cats with CKD; 14 of 25 cats responded, with adverse events observed in 12 cats, including two with possible PRCA. This retrospective study evaluated response to darbepoetin therapy, protocols for administration, and potential adverse events in dogs with CKD.
Search related documents:
Co phrase search for related documents- administration protocol and retrospective study: 1, 2, 3, 4, 5, 6
- adverse event and chronic kidney disease: 1, 2, 3, 4, 5, 6, 7, 8
- adverse event and CKD chronic kidney disease: 1, 2, 3, 4
- adverse event and CKD dog: 1
- adverse event and Darbepoetin alfa: 1
- adverse event and darbepoetin efficacy: 1
- adverse event and disease progression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- adverse event and early indicator: 1
- adverse event and frequent dosing: 1
- adverse event and kidney disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- adverse event and possible PRCA: 1
- adverse event and potential target: 1
- adverse event and previous study: 1, 2
- adverse event and retrospective study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45
- adverse event and therapeutic intervention: 1, 2
- chronic kidney disease and CKD cat: 1, 2
- chronic kidney disease and CKD chronic kidney disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76
- chronic kidney disease and CKD dog: 1, 2
- chronic kidney disease and Darbepoetin alfa: 1, 2
Co phrase search for related documents, hyperlinks ordered by date